Adults with obesity receiving tirzepatide 10 mg or 15 mg may be able to maintain most of their weight loss after switching to ...

Two phase 3b trials evaluated the efficacy and safety of tirzepatide or orforglipron for weight maintenance after injectable incretin treatment.

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide ...

New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12–15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated ...

Medications aren’t lifelong contracts. You can switch from one to another — if it’s safe for you to do so and under the guidance of a healthcare provider, of course. So, if you’re taking tirzepatide ...

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and ...

High-dose tirzepatide is associated with superior HbA1c reduction and weight loss compared with semaglutide in type 2 diabetes and obesity.

Please provide your email address to receive an email when new articles are posted on . Adults with obesity and a valid prescription can purchase 2.5 mg and 5 mg single-dose vials of tirzepatide. The ...

Lilly, the pharmaceutical giant, would love for you to believe that tirzepatide is the silver bullet we've all been waiting for — slashing your diabetes risk by 94% while you shed pounds. But dig a ...

Today, Eli Lilly launched a four-dose, single-patient use KwikPen device for its injectable obesity drug, tirzepatide (Zepbound). The device gives patients an additional, potentially more convenient ...

Sarah is an experienced writer and editor enthusiastic about helping readers live their healthiest and happiest lives. Before joining Forbes Health, Sarah worked as a writer for various digital ...